{"id":"NCT01498679","sponsor":"GlaxoSmithKline","briefTitle":"Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.","officialTitle":"A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily for 12 Weeks in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With Low to Mid-strength Inhaled Corticosteroid or Low-strength Combination Therapy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01","primaryCompletion":"2013-07","completion":"2013-07","firstPosted":"2011-12-23","resultsPosted":"2014-04-01","lastUpdate":"2017-03-08"},"enrollment":311,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"fluticasone furoate/vilanterol trifenatate","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A randomised, double-blind, placebo-controlled, parallel group multicentre study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily for 12 weeks in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with lowe to mid-strength inhaled corticosteroid or low-strength combination therapy.","primaryOutcome":{"measure":"Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period","timeFrame":"Baseline and Weeks 1-12 (up to Day 84)","effectByArm":[{"arm":"Placebo","deltaMin":-11.8,"sd":3.16},{"arm":"Fluticasone Furoate/Vilanterol 100/25 Âµg Once Daily","deltaMin":39.2,"sd":3.14}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":28,"countries":["China","Philippines","South Korea"]},"refs":{"pmids":["27401316"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":154},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Headache"]}}